Obesity and triple-negative-breast-cancer: Is apelin a new key target?

Journal of Cellular and Molecular Medicine
Florian GourguePatrice D Cani

Abstract

Epidemiological studies have shown that obese subjects have an increased risk of developing triple-negative breast cancer (TNBC) and an overall reduced survival. However, the relation between obesity and TNBC remains difficult to understand. We hypothesize that apelin, an adipokine whose levels are increased in obesity, could be a major factor contributing to both tumour growth and metastatization in TNBC obese patients. We observed that development of obesity under high-fat diet in TNBC tumour-bearing mice significantly increased tumour growth. By showing no effect of high-fat diet in obesity-resistant mice, we demonstrated the necessity to develop obesity-related disorders to increase tumour growth. Apelin mRNA expression was also increased in the subcutaneous adipose tissue and tumours of obese mice. We further highlighted that the reproduction of obesity-related levels of apelin in lean mice led to an increased TNBC growth and brain metastases formation. Finally, injections of the apelinergic antagonist F13A to obese mice significantly reduced TNBC growth, suggesting that apelinergic system interference could be an interesting therapeutic strategy in the context of obesity and TNBC.

References

Aug 30, 2000·Nature·C M PerouD Botstein
Apr 25, 2003·The New England Journal of Medicine·Eugenia E CalleMichael J Thun
Aug 21, 2003·Breast Cancer Research : BCR·Ruth C Travis, Timothy J Key
Jun 29, 2004·Journal of Clinical Pathology·P J van DiestJ P A Baak
Jan 29, 2005·Endocrinology·Jérémie BoucherPhilippe Valet
Mar 17, 2005·Journal of the National Cancer Institute·Rowan T ChlebowskiRoss Prentice
Jun 15, 2007·Oncogene·S C SorliY Audigier
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia LiedtkeLajos Pusztai
Nov 7, 2008·International Journal of Cancer. Journal International Du Cancer·Reiko SuzukiAlicja Wolk
Feb 21, 2009·The New England Journal of Medicine·Christos Sotiriou, Lajos Pusztai
Oct 5, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Thierry JardéFlorence Caldefie-Chézet
Nov 30, 2010·Carcinogenesis·Laura M Williamson, Susan P Lees-Miller
Dec 16, 2010·The Oncologist·Charles M Perou
Mar 15, 2011·Antioxidants & Redox Signaling·Thibaut DuparcClaude Knauf
Jul 5, 2011·Endocrine·Isabelle Castan-LaurellPhilippe Valet
Dec 29, 2012·Breast Cancer Research and Treatment·Markus WallwienerTanja Natascha Fehm
Jun 19, 2013·The Journal of Surgical Research·Ronny MowadRoger H Kim
Jul 23, 2013·Analytical Biochemistry·Eugene Y ZhenJesus A Gutierrez
Aug 15, 2013·The Journal of Endocrinology·Anne-Marie O'CarrollGeorge R Pope
Sep 10, 2013·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Jennifer M GierischEvan R Myers
Oct 12, 2013·International Journal of Cancer. Journal International Du Cancer·Monica BattleRuben R Gonzalez-Perez
Oct 24, 2013·British Journal of Cancer·E CopsonDiana Eccles
Oct 29, 2013·Journal of Molecular Endocrinology·Evan R Simpson, Kristy A Brown
Dec 10, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·François-Xavier PicaultYves Audigier
Dec 10, 2013·Developmental Cell·Serene C ChngBruno Reversade
Jan 29, 2014·Clinical and Experimental Medicine·Antonio LacquanitiMichele Buemi
May 27, 2014·Frontiers in Oncology·C Elizabeth Caldon
Jun 18, 2014·Nature Reviews. Endocrinology·Jiyoung ParkPhilipp E Scherer
Jul 3, 2015·International Journal of Molecular Medicine·Xuewei PengHongliang Huo
Dec 2, 2015·Cancer Causes & Control : CCC·Ping-Ping BaoYing Zheng
Oct 19, 2016·Nature Reviews. Clinical Oncology·Giampaolo BianchiniLuca Gianni
Aug 31, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R NagraniR Dikshit
Jun 13, 2017·Frontiers in Oncology·Genevieve Victoria Dall, Kara Louise Britt
Aug 2, 2017·CA: a Cancer Journal for Clinicians·Manuel Picon-RuizJoyce M Slingerland
Nov 15, 2017·Surgical Oncology Clinics of North America·Simona Maria FragomeniJacqueline S Jeruss
Mar 13, 2018·EBioMedicine·Trevor W StoneL Gail Darlington
Aug 1, 2018·Nature Medicine·Claire VinelCedric Dray
Mar 17, 2019·Cellular Oncology (Dordrecht)·Ahmad GhasemiSeyed Isaac Hashemy
Jul 4, 2019·EMBO Molecular Medicine·Iris UribesalgoJosef M Penninger
Aug 6, 2019·Frontiers in Oncology·Flora Sánchez-JiménezVíctor Sánchez-Margalet
Aug 10, 2019·Cancer Medicine·Hanna DillekåsOddbjørn Straume

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
xenografts
PCR

Software Mentioned

QuantStudio 5
Visiopharm
FELASA
GraphPad
PamGene
Living Image
GraphPad Prism

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Oncology Research and Treatment
Burcu CakarRuchan Uslu
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
Gamze Guney EskilerBerrin Tunca
Progress in Biophysics and Molecular Biology
Yang Chang-QingZhang Chen-Yan
© 2021 Meta ULC. All rights reserved